Evidence map›Paper›PMID 31465825›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2019

RETRACTED: In vitro and in vivo evaluation of degradation, toxicity, biodistribution, and clearance of silica nanoparticles as a function of size, porosity, density, and composition.

Seyyed Pouya Hadipour Moghaddam, Raziye Mohammadpour, Hamidreza Ghandehari

RetractedAbstract readRetracted Publication
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  6. Toxicity evaluation of silica nanoparticles for delivery applications.Drug delivery and translational research · 2023
    Review
  7. Article
  8. Nanoparticles for cancer therapy: a review of influencing factors and evaluation methods for biosafety.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  9. Review
  10. Article
  11. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Particle uptake driven phagocytosis in macrophages and neutrophils enhances bacterial clearance.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Seyyed Pouya Hadipour MoghaddamDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA.
Raziye MohammadpourUtah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA.
Hamidreza GhandehariDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA; Department of Bioemedical Engineering, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: hamid.ghandehari@utah.edu.

Funding

BIOLOGICAL FATE AND BIOCOMPATIBILITY OF SILICA-BASED NANOCONSTRUCTSR01ES024681 · NIEHS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Hamid Ghandehari · 2014 to 2026
$4.1M
NIEHS NIH HHS R01 ES024681
6 · The paper itself

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the corresponding author. Subsequent to the publication of the article Journal of Controlled Release 311–312 (2019) 1–15, in follow up studies in 2021, the corresponding author's lab members noticed significant discrepancies in reproducibility of some of the results reported in this manuscript. A detailed investigation in the lab was launched, and by retrieving the raw data available at the core facility pertaining to this manuscript, the following discrepancies were discovered that provide the basis for this retraction. These discrepancies have been reported to the University of Utah Research Integrity and Compliance Office by the corresponding author. The co-authors have been made aware of these discrepancies and of the decision of the corresponding author to retract. The corresponding author believes that the subject matter of this article, detailed analysis of the degradation of silica nanoparticles as a function of their physicochemical properties in relevant biological media in vitro, and in vivo, is significant. For successful utility of these particles in drug delivery applications their detailed biological fate needs to be examined. The significant discrepancies and lack of reproducibility of the reported data however is very unfortunate and the author hopes that this does not cast a doubt on the need for more detailed examination of the biological fate of silica nanoparticles in the future for their successful application in controlled release. In Vitro Data (Fig. 3) • Actual dissolution reaction volume was 2.5mL (confirmed by reviewing the lab notebook of the first author during the investigation) vs 3.5mL reported in the manuscript. • Sample volume was not used in the calculation to convert Inductively Coupled Plasma Mass Spectrometry (ICPMS) data to mg of silicon retrieved which is needed to calculate % degradation (needed to multiply data by 0.1 due to 0.1mL sample volumes). • Our investigation revealed a 20% “matrix effect with fluids” was communicated by ICPMS core facility person to the first author that was not addressed in the manuscript. • All data is different when calculating % degradation, not just by a factor of 10 due to not calculating for the 100ml sample volume. • Raw data during our investigation after publication, obtained from ICPMS facility, and not noted in the lab notebook, for day 28 of simulated lysosomal fluid (SLF) reveals n=1 and no data points for Stober100. In the manuscript however, error bars are shown for all particles at this time point and for the data for Stober100. Intracellular Degradation (Fig. 5) • Extremely high background with control causing negative % degradation for Disulfide Meso 100 from retrieved ICPMS data from core facility after publication, but manuscript shows ~1.25% degradation. • All other calculated % degradation based on retrieved data from ICPMS facility during the investigation after publication, do not match reported data in the paper. • Paper claims n=6, but raw data received from ICPMS facility during investigation (after publication) is clearly n=3. In Vivo Degradation (Fig. 6) ICPMS data retrieved during the investigation after publication for control mice showed extremely high background, and probably were not used in the calculations reported in this manuscript because it would have led to negative silicon contents for a few samples. Urine ICPMS data from the core facility was not available during investigation after publication, and cannot be retrieved from the first author's lab notebook. Hence its validity cannot be ascertained. There may be other discrepancies in the manuscript that have gone unnoticed. However, the Editor-in-Chief agrees that the above is significant enough to warrant retraction of the manuscript.

Indexed as

AnimalsAortaCell LineCell SurvivalEndothelial CellsFecesFemaleGastric JuiceHumansHydrogen-Ion ConcentrationIntestinal SecretionsLysosomesMiceNanoparticlesOsmolar ConcentrationParticle SizeSilicon DioxideBiodistributionClearanceDegradationPhysicochemical propertiesSilica nanoparticlesToxicity

Identifiers

PMID31465825
PMCPMC6874921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.